Lumason by Bracco Diagnostics is the latest ultrasound contrast agent to receive FDA approval.
The United States Food & Drug Administration (FDA) has approved the latest in a growing market of ultrasound contrast agents: Lumason by Bracco Diagnostics.
Lumason (sulfur hexafluoride lipid microbubbles) is indicated for better viewing of ultrasound images of the heart. The contrast agent is made up of gas-filled microbubbles (or microspheres) that reflect the sound waves to enhance the image, according to the FDA’s release. Lumason provides the physician with a clearer image of the patient’s left ventricle chamber and the smooth edge on the inside of the chambers of the heart, or the endocardium, the FDA said.
Lumason was evaluated in three clinical trials including 191 patients with suspected cardiac disease who had echocardiograms that were difficult to read or interpret. Lumason provided clearer images in all three trials, with visual improvement observed in the majority of patients who received a 2 milliliter dose of the agent.[[{"type":"media","view_mode":"media_crop","fid":"28417","attributes":{"alt":"Bracco logo","class":"media-image media-image-right","id":"media_crop_6420237765293","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2885","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 139px; width: 166px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]
All microbubble contrast agents, including Lumason, carry a boxed warning about the risk of serious cardiopulmonary reactions, which may be increased among patients with certain heart conditions, the FDA said.
“Sometimes echocardiograms in certain patients are difficult for physicians to see and interpret,” said Libero Marzella, MD, PhD, director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval provides doctors with another option when performing contrast enhanced ultrasound.”
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What New Research Reveals About ChatGPT and Ultrasound Detection of Thyroid Nodules
March 13th 2024In a comparison of image-to-text large language models (LLMs), ChatGPT 4.0 offered a 95 percent sensitivity rate and an 83 percent AUC that were comparable to that of two senior radiologists and one junior radiologist interacting with LLM to differentiate between malignant and benign thyroid nodules on ultrasound.
ECR Study Finds Mixed Results with AI on Breast Ultrasound
March 6th 2024While adjunctive use of AI led to significantly higher specificity and accuracy rates in detecting cancer on breast ultrasound exams in comparison to unassisted reading by breast radiologists, researchers noted that 12 of 13 BI-RADS 3 lesions upgraded by AI were ultimately benign, according to research presented at the European Congress of Radiology.